Search results
ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
1 wrz 2019 · The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart ...
1 kwi 2022 · Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients.
Fortunately, we now have a wealth of clinical trials to help us select the best management to improve the outcomes for people with HF; for many, it is now both preventable and treatable. This guideline provides practical, evidence-based recommendations.
ENTRESTO CONTAINS 2 ACTIVE INGREDIENTS THAT WORK IN DIFFERENT WAYS. The first ingredient, valsartan, has been used for years to treat Heart Failure. Valsartan reduces blood vessel tightening and the buildup of sodium and fluid. The second ingredient, sacubitril, works unlike any other Heart Failure treatment.
Entresto has been shown to be effective at treating heart failure in adults in one main study. In the study, Entresto was compared to enalapril, another medicine used for heart failure. Patients in the study had long-term heart failure with symptoms of the disease and reduced ejection fraction (the proportion of blood leaving the heart).
1 wrz 2024 · Entresto is used to treat adults with long-lasting (chronic) heart failure to help reduce the risk of death and hospitalization and to treat certain children aged 1 year and older who have symptomatic heart failure.
